The award was announced as part of the AusBiotech opening address, held at The Gold Coast Convention Centre, on Wednesday October 29th 2014.
The Emerging Company of the Year award recognises companies that have demonstrated significant achievements during the year. Johnson & Johnson Innovation’s selected Atomo Diagnostics based on its extensive commercialisation efforts with the innovative AtomoRapid™ test.
The AtomoRapid™ blood test device was developed specifically to enable users to test for a wide range of common diagnostic applications. AtomoRapid replaces existing ‘bits in box’ chemistry set test kits with a simple integrated device that makes testing easy and convenient. This enables testing to be carried out in the field by untrained users including self-testing by consumers. The company successfully launched earlier this year solutions for detection of HIV and malaria and is currently bringing to market tests for Hepatitis C, Coagulation monitoring, Allergy and Celiac’s disease.
Atomo Diagnostics Founder & CEO, John Kelly, said: “We are delighted to be recognised for the work we are doing in providing convenient, accurate and user friendly products to the market for important infectious and chronic diseases. Receiving this prestigious award sponsored by Johnson & Johnson Innovation is very encouraging.”
“Given its ease of use and simplicity, AtomoRapid™ has the ability to help transition testing out of hospital settings and into Doctor Office and at-home environments. This has the ability to materially improve both the uptake and reliability of testing in the community and helps empower patients to take more control of their health.”